Tohoku University Tohoku Medical Megabank Organization (Eiichi N. Kodama)
2021.09.17

1.   Hattori Shin-ichiro, Higashi-Kuwata Nobuyo, Hayashi Hironori, et al. A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication. Nature Communications. 2021; 12 (1): 668. doi:10.1038/s41467-021-20900-6  
2.   Oe Chihiro, Hayashi Hironori, Hirata Kazushige, et al. Pyrimidine Analogues as a New Class of Gram-Positive Antibiotics, Mainly Targeting Thymineless-Death Related Proteins. ACS Infectious Diseases. 2020; 6 (6): 1490-1500. doi:10.1021/acsinfecdis.9b00305  
3.   Saito Sho, Hayakawa Kayoko, Tsuzuki Shinya, et al. A Matched Case-Case-Control Study of the Impact of Clinical Outcomes and Risk Factors of Patients with IMP-Type Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae in Japan. Antimicrobial Agents and Chemotherapy. 2020; 65 (3): 251-257. doi:10.1128/AAC.01483-20  
4.   Nakagawara Kohsuke, Hayashi Hironori, Kawaji Kumi, et al. Application of human lymphoid cells for the evaluation of antivirals against human adenovirus type 19: Zalcitabine has superior activity compared to cidofovir. Antiviral Chemistry and Chemotherapy. 2020; 28 : 204020662092131. doi:10.1177/2040206620921319  
5.   Kuriyama Shinichi, Metoki Hirohito, Kikuya Masahiro, et al. Cohort Profile: Tohoku Medical Megabank Project Birth and Three-Generation Cohort Study (TMM BirThree Cohort Study): rationale, progress and perspective. International Journal of Epidemiology. 2020; 49 (1): 18-19m. doi:10.1093/ije/dyz169  
6.   Sugawara Junichi, Ishikuro Mami, Obara Taku, et al. Maternal Baseline Characteristics and Perinatal Outcomes: The Tohoku Medical Megabank Project Birth and Three-Generation Cohort Study. Journal of Epidemiology. 2020; : . doi:10.2188/jea.JE20200338  
7.   Oikawa Yoshitsugu, Izumi Rumiko, Koide Masashi, et al. Mitochondrial dysfunction underlying sporadic inclusion body myositis is ameliorated by the mitochondrial homing drug MA-5. PLOS ONE. 2020; 15 (12): e0231064. doi:10.1371/journal.pone.0231064  
8.   Tsuboi Akito, Matsui Hiroyuki, Shiraishi Naru, et al. Design and Progress of Oral Health Examinations in the Tohoku Medical Megabank Project. The Tohoku Journal of Experimental Medicine. 2020; 251 (2): 97-115. doi:10.1620/tjem.251.97  
9.   Siarot Lowela, Chutiwitoonchai Nopporn, Sato Hirotaka, et al. Identification of human immunodeficiency virus type-1 Gag-TSG101 interaction inhibitors by high-throughput screening. Biochemical and Biophysical Research Communications. 2018; 503 (4): 2970-2976. doi:10.1016/j.bbrc.2018.08.079  
10.   Kikuchi Haruhisa, Kawai Kosuke, Nakashiro Yota, et al. Construction of a Meroterpenoid‐Like Compounds Library Based on Diversity‐Enhanced Extracts. Chemistry – A European Journal. 2018; 25 (4): chem.201805417. doi:10.1002/chem.201805417  
11.   Watanabe Masahiro, Hashimoto Koichi, Abe Yusaku, et al. A Novel Peptide Derived from the Fusion Protein Heptad Repeat Inhibits Replication of Subacute Sclerosing Panencephalitis Virus In Vitro and In Vivo. PLOS ONE. 2016; 11 (9): e0162823. doi:10.1371/journal.pone.0162823  
12.   Salie Zhe Li, Kirby Karen A., Michailidis Eleftherios, et al. Structural basis of HIV inhibition by translocation-defective RT inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA). Proceedings of the National Academy of Sciences. 2016; 113 (33): 9274-9279. doi:10.1073/pnas.1605223113  
13.   Miyamoto Fusako, Kawaji Kumi, Oishi Shinya, et al. Anti-HIV-1 activity determined by β-galactosidase activity in the multinuclear activation of an indicator assay is comparable with that by a conventional focus counting method. Antiviral Chemistry and Chemotherapy. 2015; 24 (2): 77-82. doi:10.1177/2040206615614164  
14.   Asai Teigo, Tsukada Kento, Ise Satomi, et al. Use of a biosynthetic intermediate to explore the chemical diversity of pseudo-natural fungal polyketides. Nature Chemistry. 2015; 7 (9): 737-743. doi:10.1038/nchem.2308  
15.   Hachiya Atsuko, Reeve Aaron B, Marchand Bruno, et al. Evaluation of Combinations of 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine with Clinically Used Antiretroviral Drugs. Antimicrobial Agents and Chemotherapy. 2013; 57 (9): 4554-4558. doi:10.1128/AAC.00283-13  
16.   Shimane Kazuki, Kawaji Kumi, Miyamoto Fusako, et al. HIV-1 Resistance Mechanism to an Electrostatically Constrained Peptide Fusion Inhibitor That Is Active against T-20-Resistant Strains. Antimicrobial Agents and Chemotherapy. 2013; 57 (8): 4035-4038. doi:10.1128/AAC.00237-13  
17.   Maeda Kenji, Desai Darshan V, Aoki Manabu, et al. Delayed emergence of HIV-1 variants resistant to 4’-ethynyl-2-fluoro-2’-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001. Antiviral Therapy. 2013; 19 (2): 179-189. doi:10.3851/IMP2697